TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9591497

Group type: EXPERIMENTAL
Intervention: Oral HRT (2 mg of estradiol on days 1‐12, 2 mg of estradiol plus 1 mg of norethisterone acetate on days 13‐22, and 1 mg of estradiol on days 23‐28; n = 21)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transdermal HRT (50 microg/d of estradiol on days 1‐28 followed by 250 microg/d of norethisterone acetate on days 14‐28; n = 21)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Transdermal HRT (50 microg/d of estradiol on days 1‐28 followed by 250 microg/d of norethisterone acetate on days 14‐28; n = 10 female smokers)
Number of subjects: 52
Study: 7843948

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 3348073

Group type: EXPERIMENTAL
Intervention: Dixyrazine 0.5 mg kg‐1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine-scopolamine 0.15 mg kg‐1 and 0.0065 mg kg‐1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29277968

Group type: EXPERIMENTAL
Intervention: Liraglutide (0.9 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin monotherapy (placebo)
Number of subjects: 0
Study: 27374748

Group type: EXPERIMENTAL
Intervention: Alisporivir (Debio 025) in combination with pegylated interferon‐α2a
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 26359998

Group type: EXPERIMENTAL
Intervention: High-potency topical corticosteroid (betamethasone dipropionate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo saline solution
Number of subjects: 16
Study: 23484344

Group type: EXPERIMENTAL
Intervention: High group entitativity condition
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Medium group entitativity condition
Number of subjects: 215

Group type: COMPARATOR
Intervention: Low group entitativity condition
Number of subjects: 215
Study: 20569291

Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen mixture (NOOM) inhalation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Lidocaïne-prilocaïne cream (LPC) application
Number of subjects: 41
Study: 19105582

Group type: EXPERIMENTAL
Intervention: Suggestive materials leading to false beliefs about a negative experience with Pluto.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suggestive materials leading to a positive experience with Pluto.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: False beliefs induced by negative suggestions.
Number of subjects: 0
Study: 16958738

Group type: EXPERIMENTAL
Intervention: Topical subgingival application of doxycycline hyclate (DH) gel adjunctive to non-surgical periodontal therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 18
Study: 12648557

Group type: EXPERIMENTAL
Intervention: Bicarbonate-containing gum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard sugar-free gum
Number of subjects: 20
Study: 10611130

Group type: EXPERIMENTAL
Intervention: Occluded glasses (left lens occluded)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Unoccluded glasses (no occlusion)
Number of subjects: 143
Study: 9537145

Group type: EXPERIMENTAL
Intervention: Manual keratometry (MK)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Automated keratometry (AK)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Comparison of MK and AK
Number of subjects: 52
Study: 1549964

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 50
Study: 2435071

Group type: EXPERIMENTAL
Intervention: Electrophysiologically guided antiarrhythmic drug therapy (group I)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Metoprolol (daily dose up to 200 mg) without invasive testing (group II)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Metoprolol (group III)
Number of subjects: 166
Study: 30591031

Group type: EXPERIMENTAL
Intervention: Valerian capsules taken 60 minutes before bedtime for one month
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo capsules taken 60 minutes before bedtime for one month
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Valerian capsules
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 39
Study: 27747224

Group type: EXPERIMENTAL
Intervention: Ling Zhi preparation (3,000 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ling Zhi preparation (3,000 mg) with ascorbic acid (2,500 mg)
Number of subjects: 12
Study: 25381393

Group type: EXPERIMENTAL
Intervention: DPYD*2A variant
Number of subjects: 2886

Group type: EXPERIMENTAL
Intervention: D949V variant
Number of subjects: 2886

Group type: EXPERIMENTAL
Intervention: I560S variant
Number of subjects: 2886
Study: 22659339

Group type: EXPERIMENTAL
Intervention: Phosphate monomer containing resin (Panavia 21 TC; N=16)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesive bonding system with a phosphoric acid acrylate primer (Multilink‐Automix with Metal/Zirconia primer; N=14)
Number of subjects: 30
Study: 20115947

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18617735

Group type: EXPERIMENTAL
Intervention: Absolute quantification of N-acetylaspartate concentration in the hippocampus
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Absolute quantification of N-acetylaspartate concentration in the anterior periventricular and deep white matter
Number of subjects: 69

Group type: COMPARATOR
Intervention: Relative ratio using creatine as a reference
Number of subjects: 69
Study: 16011291

Group type: EXPERIMENTAL
Intervention: Acanthopanax senticosus injection (ASI) for 21 days
Number of subjects: 73
Study: 11836281

Group type: EXPERIMENTAL
Intervention: 1000 mg TU im at wk 2, 6, 12, and 18 combined with 200 mg NETE im at wk 0, 6, 12, and 18 (group I)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1000 mg TU im at wk 2, 6, 12, and 18 combined with 400 mg NETE im at wk 0, 6, 12, and 18 (group II)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 1000 mg TU im at wk 2, 6, 12, and 18 with daily oral NET acetate (NETA) from wk 0 to 24 (group III)
Number of subjects: 26
Study: 10516537

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.i.d. orally for 14 days (CL group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clarithromycin plus cefuroxime 500 mg b.i.d. orally for 7 days (CLCE group)
Number of subjects: 90
Study: 7488598

Group type: EXPERIMENTAL
Intervention: 1% topical apraclonidine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.5% topical levobunolol
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 500 mg oral acetazolamide
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Corneoscleral tunnel technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Corneoscleral suture technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Experienced surgeons
Number of subjects: 100

Group type: COMPARATOR
Intervention: Inexperienced surgeons
Number of subjects: 100
Study: 1974502

Group type: EXPERIMENTAL
Intervention: Carvedilol (5 mg intravenously)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Propranolol (6 mg intravenously)
Number of subjects: 17
Study: 6118983

Group type: EXPERIMENTAL
Intervention: Sudden cancellation of psychotropic drugs (with modifications such as combinations with sulfozine and diuretics)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Psychopharmacotherapy not interrupted (Control group)
Number of subjects: 64
Study: 31999799

Group type: EXPERIMENTAL
Intervention: Overweight/obese group
Number of subjects: 153

Group type: COMPARATOR
Intervention: Healthy weight group
Number of subjects: 153
Study: 30947636

Group type: EXPERIMENTAL
Intervention: mHealth
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: mHealth treatment responders
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: mHealth nonresponders
Number of subjects: 163

Group type: COMPARATOR
Intervention: Clinic-based care
Number of subjects: 163
Study: 29270003

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of telmisartan 40 mg and S-amlodipine 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant administration of telmisartan 40 mg and S-amlodipine 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (FDC and concomitant administration)
Number of subjects: 0
Study: 26424421

Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23819227

Group type: EXPERIMENTAL
Intervention: Abdominal cluster‐needling therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 70
Study: 21272382

Group type: EXPERIMENTAL
Intervention: Self management intervention
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 176
Study: 19341989

Group type: EXPERIMENTAL
Intervention: Yoga classes (twice weekly for 90 minutes over two months)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 65
Study: 16881929

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient Sprinkles with 12.5 mg iron as ferrous fumarate
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient Sprinkles with 20 mg iron as ferrous fumarate
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient Sprinkles with 30 mg iron as ferrous fumarate
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient Sprinkles with 20 mg iron as ferric pyrophosphate
Number of subjects: 133

Group type: COMPARATOR
Intervention: Iron drops with 12.5 mg iron as liquid ferrous sulphate
Number of subjects: 133
Study: 15450574

Group type: EXPERIMENTAL
Intervention: Cisplatin (80 mg/m(2)) and docetaxel (60 mg/m(2)) chemotherapy prior to surgery (neoadjuvant group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (surgery without any previous chemotherapy)
Number of subjects: 38
Study: 11264760

Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg twice daily via Turbuhaler
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg twice daily via Turbuhaler
Number of subjects: 350

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) 400 microg daily via pMDI
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg daily via Turbuhaler
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Budesonide (both doses)
Number of subjects: 350
Study: 9679718

Group type: EXPERIMENTAL
Intervention: Dopamine (5 microg x kg(‐1) x min(‐1))
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8109545

Group type: EXPERIMENTAL
Intervention: Lipid-lowering diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 2679681

Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin (1 g:2 g)
Number of subjects: 80

Group type: COMPARATOR
Intervention: mezlocillin/oxacillin (2 g:1 g)
Number of subjects: 80
Study: 1099501

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy consisting of DTIC with adriamycin, CCNU, or hydroxyurea.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with adriamycin and DTIC.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy consisting of DTIC with other agents (adriamycin, CCNU, hydroxyurea).
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy consisting of DTIC with other agents.
Number of subjects: 110
Study: 31092132

Group type: EXPERIMENTAL
Intervention: Full squat (F-SQ)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Parallel squat (P-SQ)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Half squat (H-SQ)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (training cessation)
Number of subjects: 53
Study: 30839405

Group type: EXPERIMENTAL
Intervention: Salbutamol (Ventolin) by nebulization (Group B; n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular insulin bolus with glucose infusion (Group A; n = 20)
Number of subjects: 40
Study: 26786294

Group type: EXPERIMENTAL
Intervention: Prenatal lifestyle intervention (dietary counselling twice by phone and access to twice‐weekly exercise groups during pregnancy)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Standard prenatal care (control group)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Prenatal lifestyle intervention (compliant participants)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Prenatal lifestyle intervention
Number of subjects: 606

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 606
Study: 26817181

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 184

Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 184
Study: 23219570

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) as an adjunct to usual care
Number of subjects: 469

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 469
Study: 22240882

Group type: EXPERIMENTAL
Intervention: Total occlusive ionic silver‐containing dressing (TOISD) combination
Number of subjects: 166

Group type: COMPARATOR
Intervention: No dressing (control group)
Number of subjects: 166
Study: 19204598

Group type: EXPERIMENTAL
Intervention: Recreational walking, moderate recreational PA, and strenuous recreational PA
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Mild recreational PA
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Moderate to strenuous recreational PA
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Total recreational PA
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Yard activities
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Household activities
Number of subjects: 1092
Study: 16948718

Group type: EXPERIMENTAL
Intervention: Current standard of care plus consultation with a nurse
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Current standard of care plus consultation with a nurse and home visitor
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Current standard of physician care
Number of subjects: 1352
Study: 14716266

Group type: EXPERIMENTAL
Intervention: Hero 642
Number of subjects: 30

Group type: COMPARATOR
Intervention: K3
Number of subjects: 30

Group type: COMPARATOR
Intervention: Profile
Number of subjects: 30
Study: 11740307

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3-g Cr.kg(‐1) body weight for the first 5 days, then 0.07-g Cr.kg(‐1) body weight)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine supplementation and Placebo
Number of subjects: 30
Study: 9236571

Group type: EXPERIMENTAL
Intervention: Tacrine hydrochloride (160 mg/d)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 8233288

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 316
Study: 3652281

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (2 g single dose)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pipemidic acid (two 200 mg doses daily for 7 days)
Number of subjects: 51
Study: 31906976

Group type: EXPERIMENTAL
Intervention: Hypoxia + CHO (6% maltodextrin)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hypoxia + Placebo
Number of subjects: 8
Study: 31065701

Group type: EXPERIMENTAL
Intervention: SKIP (every other day feeding)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 4/3 (4 days feeding and 3 nonconsecutive fasting days)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 5/2 (5 days feeding and 2 nonconsecutive fasting days)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: DAILY (every day feeding)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 4/3 and 5/2 feeding programs
Number of subjects: 1400
Study: 28544490

Group type: EXPERIMENTAL
Intervention: No suction drain (study group)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Suction drain (control group)
Number of subjects: 176
Study: 25136887

Group type: COMPARATOR
Intervention: IV adenosine (140 µg/kg/min)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IV bolus regadenoson injection (400 µg)
Number of subjects: 100
Study: 23440173

Group type: EXPERIMENTAL
Intervention: Ask-Advise-Connect (AAC)
Number of subjects: 2052

Group type: COMPARATOR
Intervention: Ask. Advise. Refer. (AAR)
Number of subjects: 2052
Study: 21669426

Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 600

Group type: COMPARATOR
Intervention: COC
Number of subjects: 600
Study: 18268247

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (1,200 mg/day)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 170
Study: 16564589

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) with one submandibular gland spared
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intensity Modulated Radiotherapy (IMRT) with no submandibular gland spared
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT) with contralateral submandibular gland spared
Number of subjects: 36
Study: 12658027

Group type: EXPERIMENTAL
Intervention: Intensive diastolic blood pressure lowering (DBP < or = 85 mmHg and < or = 80 mmHg)
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Less aggressive target group (DBP < 90 mmHg)
Number of subjects: 18790
Study: 10817799

Group type: EXPERIMENTAL
Intervention: Digoxin (0.25 mg intravenous administration)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9007147

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCP) administered for 28-42 days followed by menotropin treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Previous cycles (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: OCP treatment cycles
Number of subjects: 42
Study: 1800877

Group type: EXPERIMENTAL
Intervention: Fentanyl (less than 100 micrograms/kg) combined with diazepam (less than 0.2 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Higher doses of fentanyl combined with diazepam (greater than that used in Group I)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Higher doses of fentanyl combined with diazepam
Number of subjects: 16
Study: 6139120

Group type: EXPERIMENTAL
Intervention: Midazolam with pethidine
Number of subjects: 185

Group type: COMPARATOR
Intervention: Diazepam with pethidine
Number of subjects: 185
Study: 30849239

Group type: EXPERIMENTAL
Intervention: 140 ml of 'BEET It sport®' NO3‐ shot containing 12.8 mmol or 800 mg of NO3‐
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 140 ml of 'BEET It sport®' NO3‐ shot
Number of subjects: 11
Study: 31062253

Group type: EXPERIMENTAL
Intervention: duloxetine 30 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: gabapentin 300 mg
Number of subjects: 150

Group type: COMPARATOR
Intervention: acetaminophen 1000 mg
Number of subjects: 150
Study: 30576330

Group type: EXPERIMENTAL
Intervention: Nurse-led liver health clinic
Number of subjects: 910

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Nurse-led case finding
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: GP referrals
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: AUDIT questionnaire mailouts
Number of subjects: 910
Study: 27787564

Group type: EXPERIMENTAL
Intervention: Cranberry capsules (72 mg total, equivalent to 20 ounces of cranberry juice) administered once a day
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo administered once a day
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 185
Study: 24952712

Group type: EXPERIMENTAL
Intervention: Ages and Stages Questionnaire (ASQ) at 3 years of age
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development, Second Edition (BSID-II) scores at 14 months
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Medical history including growth, feeding, and complications
Number of subjects: 203

Group type: COMPARATOR
Intervention: Type of shunt
Number of subjects: 203
Study: 21771570

Group type: EXPERIMENTAL
Intervention: Compression rate of 80 min(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Compression rate of 160 min(‐1)
Number of subjects: 20
Study: 20213208

Group type: EXPERIMENTAL
Intervention: CRC educational video in Spanish on a portable personal digital video display device, accompanied by a brochure and a patient-delivered reminder for their physician.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Not applicable (control group).
Number of subjects: 65
Study: 18065878

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (11.6 U/kg, range 9.7-14.8) administered preoperatively
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no botulinum toxin)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 11207693

Group type: EXPERIMENTAL
Intervention: 585 nm pulsed dye laser treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Silicone gel sheeting (Control)
Number of subjects: 11
Study: 9259163

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 3028

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 3028
Study: 7518406

Group type: EXPERIMENTAL
Intervention: recombinant aprotinin
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41
Study: 3555062

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 300 mg every 12 hours
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 200 mg every 12 hours
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin orally after initial intravenous therapy
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin
Number of subjects: 34
Study: 30047564

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Velpatasvir (VEL) quantified using a novel LC–MS/MS method; dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internal standard (ledipasvir) used in the quantification method.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Developed method for plasma sample analysis.
Number of subjects: 0